Complicanze trombotiche nel mieloma multiplo Mauro Berrettini S.C. Medicina Generale-DH Oncologico Ospedale di Orvieto Mediterranean School of Oncology.

Slides:

Advertisements

Similar presentations

Venous Thromboembolism: Risk Assessment and Prophylaxis

Advertisements

Unique Challenges in MPNs 2012 Bay Area MPN Patient Symposium Laura C. Michaelis, MD Loyola University Medical Center.

LHD Logo Venous Thromboembolism Reducing the Risk DATE.

PLASMA CELL DYSCRASIAS Monoclonal gammopathy of uncertain significance (MGUS)  Idiopathic  Associated with other diseases (autoimmune, infectious, non-heme.

Staff Oncologist, Mayo Clinic Arizona

+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.

Results: 1.Progression of thrombus length and volume (40% vs. 28%; P

Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.

Prophylaxis of Venous Thromboembolism

Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.

The Art of Medical Prophylaxis, Impacting the Patient Early Anna Falanga, MD Hemostasis and Thrombosis Center Hematology-Oncology Dept Ospedali Riuniti.

Risk of VTE – when is anticoagulation required treatment of VTE – what is optimum anticoagulant survival advantage with heparins new anticoagulants – how.

Venous ThromboEmbolism

Palumbo A et al. Proc ASH 2012;Abstract 446.

DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

1 FDA Review of Clinical Data Fragmin ® (Dalteparin sodium injection) for treatment of VTE in cancer patients Medical Officer: Andrew Dmytrijuk, MD FDA/Center.

Venous Thromboembolism

Cancer-Associated Thrombosis

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.

Obesity and Venous Thromboembolic Disease Angel Galvez MD PhD Oncology Specialists SC Lutheran General Hospital.

HICKMAN CATHETER Thrombotic complications associated with venous access devic Thrombotic complications associated with venous access devices Occlusion.

VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.

Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.

DVT Prevention and Anticoagulant Management

VTE prevention and anticoagulation practice VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis Nurse RCHT.

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,

ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:

Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after major knee surgery KA Bauer, BI Eriksson,

Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,

Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin mg/d Prophylactic LMWH Therapeutic.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.

Antithrombotic Therapy for VTE: CHEST Guidelines 2016

Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.

Sclerotherapy and thrombophilia: How to do it? Saturday 29 March 2014 Pascal Giordana Nice, France.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.

Taylor Butler, PharmD, BCOP Decentralized Clinical Pharmacist

The VERITY Steering Committee

Attal M et al. Proc ASH 2010;Abstract 310.

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Fatimah Al-Ani 1,2,. MD MRCP, Jose Maria Bastida Bermejo3,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Selecting MM Therapy in Patients With Comorbidities

New Oral Anticoagulants and VTE Management

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

A Better Solution For Cancer Patients With VTE?

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Presentation transcript:

Complicanze trombotiche nel mieloma multiplo Mauro Berrettini S.C. Medicina Generale-DH Oncologico Ospedale di Orvieto Mediterranean School of Oncology Orvieto 22 Novembre 2009

Hemostasis-related complications in plasma cell dyscrasias thrombocytopenia endothelial damage acquired von Willebrand disease acquired APC resistance heparin-like anticoagulants hypofibrinolisis clotting factor deficiencies increased F.VIII/vWF amyloidosis lupus anticoagualant Bleeding Thrombosis

Incidence of deep vein thrombosis (DVT) in monoclonal gammopathy (MGUS) and multiple myeloma(MM) US VA hospital records ( ) Incidence R.R 1000 pt/years General ( ) 0.9 MGUS (2374) MM ( 6192) Kristinsson S.Y.et al, Blood 2008;112:

MGUS MM C Kristinsson SY et al., Blood 2008,112:

High variability due: Age History venous thromboembolism(VTE) Stage of the disease Hypercoagulability Immobilization CVC Comorbidities Therapy: chemotherapies, immunomodulatory drugs (thalidomide,lenalidomide) Incidence of deep vein thrombosis (DVT) in monoclonal gammopathy (MGUS) and multiple myeloma(MM)

Eby C., British Journal of Haematology, 2009; 145,

Meta-analysis of the incidence of venous thromboembolic events with induction thalidomide Hicks L.K. et al.,, Cancer Treatment Rewies,2008; 34:

Meta-analysis of the incidence of venous thromboembolic events with maintenance thalidomide Hicks L.K. et al.,, Cancer Treatment Rewies,2008; 34:

Clinical studies of thromboprophylaxis in MM patients receiving thalidomide or lenalidomide Falanga A, Marchetti M., J.Clin.Onc.2009;27:

Meta-analysis of the incidence of venous thromboembolic events with induction thalidomide Hicks L.K. et al.,, Cancer Treatment Rewies,2008; 34:

Prevention of venous thromboembolism (VTE) in MM “In the absence of clear data from randomized studies,….. …..proposed strategies are the result of common sense…… ……further investigation is needed to define the best VTE prophylaxis…..” The International Myeloma Working Group PalumboA. et al., Leukemia 2008;22:

Prevention of VTE in MM Which drug? efficacy safety ASA yes/? yes/? Warfarin Low fixed dose no yes Therapeutic dose yes no/? Low m.w.heparin yes yes

Prevention of VTE in MM patients receiving thalidomide or lenalidomide? When? Which Patient? At higher risk: Induction therapy High dose dexametasone, doxorubicine Multiagent chemotherapy + other risk factors: age, history of VTE, CVC, comorbidities, immobilization The International Myeloma Working Group Palumbo A. et al., Leukemia 2008;22: